Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.

            Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

            Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

            FOR 30+ YEARS, OUR
            USE THE POWER OF
            SCIENCE TO BRING
            NEW MEDICINES TO
            PATIENTS... OVER
            AND OVER AGAIN.

            Neil Stahl, PhD, Executive VP,
            Research and Development
            2019 annual report PDF download

            Check out our 2019 annual materials. The Responsibility Report and Annual Report are now online.

            Read our annual report
            and responsibility report

            2019 responsibility report PDF download


            • 30+
              years of scientific
            • 8,100+
            • ~1,100+
              employees with
              an MD, PhD or
              PharmD degree
            • 6TH
              consecutive year
              in Forbes’ World’s
              Most Innovative
            • #1
              ranking in Science
              magazine’s global Top
              Employer survey for six
              of the past nine years
            • 31,000+
              employee volunteer hours
              for 100+ organizations
              in 2018
            • 7
            • 98%
              of our waste
              diverted from
              landfill, surpassing
              our goal
            • 100%
              of drug candidates
              invented and
              developed in-house
            • 1M+
              exomes sequenced
              to date
            • 200+
              peer-reviewed publications
              in 2019
            • 20+
              product candidates in
              clinical development
              across multiple
              therapeutic areas
            • Fortune: Best Companies to Work for, 2020

              Newsweek, America’s Most Responsible Companies, 2020

              IDEA Pharma, Pharmaceutical Invention Index, 2019

              RobecoSAM and S&P Dow Jones Indices: Dow Jones Sustainability World Index, 2019

              Science: Top Employer, 2019

              Harvard Business Review: Best Performing CEOs, 2019

            • Civic 50: Most Community-Minded Companies in the Nation, 2019

              Fast Company: Best Workplaces for Innovators, 2019

              Shingo Institute: The Shingo Prize, 2019

              Great Places to Work: Best Workplace in Ireland, 2019

              Forbes: Top 10 Most Innovative Companies, 2018


            We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

            Our leadership

            A FOCUS
            ON SCIENCE

            From our first days, science has remained our central guiding principle.

            Our journey